MedPath

Study of V117957 in Overactive Bladder Syndrome

Phase 1
Completed
Conditions
Overactive Bladder Syndrome
Interventions
Drug: Placebo
Registration Number
NCT06024642
Lead Sponsor
Imbrium Therapeutics
Brief Summary

The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with overactive bladder syndrome, compared to placebo.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
51
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
V117957V117957-
PlaceboPlacebo-
Primary Outcome Measures
NameTimeMethod
Change from baseline in number of micturition episodes per 24 hours and number of incontinence episodes per 24 hours.Baseline, Weeks 2, 4, 6, 8, and 9
Change from baseline in volume voided per 24 hours.Baseline, Weeks 2, 4, 6, 8, and 9
Secondary Outcome Measures
NameTimeMethod
Change from baseline in Overactive Bladder Questionnaire: Long-Form, 1-week Recall (OAB-q LF)Baseline, Weeks 2, 4, 6, 8, and 9

The OAB-q LF is a 33-item, condition-specific measure designed to assess the impact of OAB symptoms on Health-related Quality of Life (HRQL).

Change from baseline in Patient Perception of Bladder Condition (PPBC)Baseline, Weeks 2, 4, 6, 8, and 9

The PPBC is a single item that assesses the patients' subjective impression of their current urinary problem.

Change from baseline in Patient Perception of Intensity of Urgency Scale (PPIUS)Baseline, Weeks 2, 4, 6, 8, and 9

The PPIUS is a 5-point scale designed for measurement of both urinary urgency and urge incontinence.

Change from baseline in Subject Global Response Assessment (SGRA)Baseline, Weeks 2, 4, 6, 8, and 9

The SGRA is a self-rated balanced measure of subject's clinical condition relative to baseline.

Change from baseline in Symptom Impact Sleep Questionnaire (SISQ)Baseline, Weeks 2, 4, 6, 8, and 9

The SISQ contains 2 questions that assess the quality of sleep and the impact of the subject's symptoms of OAB on sleep.

Trial Locations

Locations (12)

Bay State Clinical Trials, Inc.

🇺🇸

Watertown, Massachusetts, United States

Arizona Urology Specialists, PLLC

🇺🇸

Tucson, Arizona, United States

Providea Health Partners, LLC

🇺🇸

Evergreen Park, Illinois, United States

Hope Clinical Research, LLC

🇺🇸

Canoga Park, California, United States

AccuMed Research Associates

🇺🇸

Garden City, New York, United States

ARK Clinical Research

🇺🇸

Long Beach, California, United States

Ochsner LSU Health Shreveport - Regional Urology

🇺🇸

Shreveport, Louisiana, United States

The Clinical Trial Center, LLC

🇺🇸

Jenkintown, Pennsylvania, United States

Urology Group of Southern California

🇺🇸

Los Angeles, California, United States

Boston Clinical Trials

🇺🇸

Boston, Massachusetts, United States

Unified Women's Clinical Research-Lyndhurst

🇺🇸

Winston-Salem, North Carolina, United States

DelRicht Research

🇺🇸

New Orleans, Louisiana, United States

© Copyright 2025. All Rights Reserved by MedPath